Practice Areas
Licensing & IP
In-licensing and out-licensing are the primary vehicles for portfolio building in biotech. The deal structure (exclusivity, field of use, royalty benchmarks, option timing) depends on the stage of development, the patent landscape, and the anticipated commercial pathway. License structures that do not anticipate timeline shifts create disputes years later, when commercialization pathways diverge from initial assumptions.
- Exclusive and non-exclusive license agreements
- Option agreements with milestone gates
- Royalty structures and benchmarking
- Field-of-use and territorial restrictions
Research Collaborations
Sponsored research, CRO partnerships, and academic collaborations require careful IP allocation and publication frameworks. Research assets created upstream (compounds, data, know-how) must flow downstream to commercial development without encumbrance.
- Collaboration agreements with milestone structures
- Sponsored research agreements
- Material transfer agreements
- Consortium agreements with multi-party governance
Clinical Development
Clinical contracts span multiple jurisdictions and regulatory systems, from the EU CTR and ICH-GCP to Swiss KlinV. Each agreement (with CROs, investigators, and trial sites) must support both the regulatory submission strategy and the broader commercial development timeline.
- Clinical trial agreements
- CRO master services agreements
- Investigator and site contracts
- Manufacturing and supply agreements (CMO/CDMO)
Fixed-Fee Deliverables
For the most requested standardized deliverables in this industry, the firm publishes the fixed fee directly. Standard turnaround is 48 to 72 hours; a 24-hour priority track is available at a 50 percent uplift, subject to capacity. The full list and terms are on the Fee Structure page.
Quality Agreement (GMP / GDP)
The GMP / GDP responsibility-allocation agreement for supply relationships, with a complete responsibility matrix and the non-delegable Swiss positions checked. Fixed fee CHF 4,500; multi-site or combination products from CHF 6,000. 72-hour turnaround.
- Responsibility matrix with one accountable party per activity
- Change-control clause; the commercial supply agreement is scoped separately
- Senior review before anything leaves the firm
International Data-Transfer Package
The documented transfer assessment for clinical, pharmacovigilance and research data flows: mechanism selection, the six-step transfer impact assessment, the correct SCC module with the Swiss addendum, and a rated conclusion. Fixed fee CHF 6,200 per vendor; each further vendor CHF 2,500 to 3,500. 72-hour turnaround.
- Documented six-step assessment, importer-specific
- Rated conclusion with re-assessment triggers
- Per-vendor reuse pricing
Getting Started
Most engagements begin with a scoping call to define the matter, regulatory context, and timeline. From there, the engagement is structured around a value-based fee arrangement (fixed, capped, phased, or a retainer or subscription) matched to the scope, with hourly rates reserved for work beyond the agreed scope.
For companies needing ongoing support without a full-time hire, fractional counsel arrangements provide continuity across the contract portfolio and regulatory landscape.
Biotech and pharma matters are handled through these services:
Selected analysis from the firm's insights: